Iranian Journal of Psychiatry and Behavioral Sciences

Published by: Kowsar

Acceptance and Commitment Therapy, Selective Serotonin Reuptake Inhibitors and Their Combination in the Improvement of Obsessive-Compulsive Symptoms and Experiential Avoidance in Patients With Obsessive-Compulsive Disorder

Yaghoob Vakili 1 , * , Banafsheh Gharaee 2 and Mojtaba Habibi 3
Authors Information
1 Department of Clinical Psychology, School of Medicine, North Khorasan University of Medical Sciences, Bojnord, IR Iran
2 Department of Clinical Psychology, Tehran Psychiatric Institute, Iran University of Medical Sciences, Tehran, IR Iran
3 Departments of Family Therapy, Family Research Institute, University of Shahid Beheshty, Tehran, IR Iran
Article information
  • Iranian Journal of Psychiatry and Behavioral Sciences: June 28, 2015, 9 (2)
  • Published Online: June 1, 2015
  • Article Type: Original Article
  • Received: December 20, 2013
  • Revised: June 20, 2014
  • Accepted: September 5, 2014
  • DOI: 10.17795/ijpbs845

To Cite: Vakili Y, Gharaee B, Habibi M. Acceptance and Commitment Therapy, Selective Serotonin Reuptake Inhibitors and Their Combination in the Improvement of Obsessive-Compulsive Symptoms and Experiential Avoidance in Patients With Obsessive-Compulsive Disorder, Iran J Psychiatry Behav Sci. 2015 ; 9(2):-. doi: 10.17795/ijpbs845.

Abstract
Copyright © 2015, Mazandaran University of Medical Sciences.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Wfsbp Task Force on Treatment Guidelines for Anxiety O, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry. 2008; 9(4): 248-312[DOI][PubMed]
  • 2. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB, American Psychiatric A. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007; 164(7 Suppl): 5-53[PubMed]
  • 3. Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004; 24(8): 1011-30[DOI][PubMed]
  • 4. Rosa-Alcazar AI, Sanchez-Meca J, Gomez-Conesa A, Marin-Martinez F. Psychological treatment of obsessive-compulsive disorder: a meta-analysis. Clin Psychol Rev. 2008; 28(8): 1310-25[DOI][PubMed]
  • 5. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 1995; 52(1): 53-60[PubMed]
  • 6. Fisher PL, Wells A. How effective are cognitive and behavioral treatments for obsessive-compulsive disorder? A clinical significance analysis. Behav Res Ther. 2005; 43(12): 1543-58[DOI][PubMed]
  • 7. Hayes SC, Strosahl K, Wilson KG. Acceptance and Commitment Therapy: An Experiential Approach to Behavior Change. 2003;
  • 8. Hayes SC, Strosahl KD, Wilson KG. Acceptance and Commitment Therapy, Second Edition: The Process and Practice of Mindful Change. 2011;
  • 9. Hayes SC. Acceptance and commitment therapy, relational frame theory, and the third wave of behavioral and cognitive therapies. Behavi Ther. 2004; 35(4): 639-65
  • 10. Eifert GH, Forsyth JP. Acceptance & Commitment Therapy for Anxiety Disorders: A Practitioner's Treatment Guide to Using Mindfulness, Acceptance, and Values-based Behavior Change Strategies. 2005;
  • 11. Abramowitz JS, Lackey GR, Wheaton MG. Obsessive-compulsive symptoms: the contribution of obsessional beliefs and experiential avoidance. J Anxiety Disord. 2009; 23(2): 160-6[DOI][PubMed]
  • 12. Briggs ES, Price IR. The relationship between adverse childhood experience and obsessive-compulsive symptoms and beliefs: the role of anxiety, depression, and experiential avoidance. J Anxiety Disord. 2009; 23(8): 1037-46[DOI][PubMed]
  • 13. Wheaton MG, Abramowitz JS, Franklin JC, Berman NC, Fabricant LE. Experiential avoidance and saving cognitions in the prediction of hoarding symptoms. Cogn Ther Res. 2011; 35(6): 511-6
  • 14. Twohig MP. A randomized clinical trial of acceptance and commitment therapy versus progressive relaxation training in the treatment of obsessive compulsive disorder [Dissertation]. 2007;
  • 15. Twohig MP, Hayes SC, Plumb JC, Pruitt LD, Collins AB, Hazlett-Stevens H, et al. A randomized clinical trial of acceptance and commitment therapy versus progressive relaxation training for obsessive-compulsive disorder. J Consult Clin Psychol. 2010; 78(5): 705-16[DOI][PubMed]
  • 16. Twohig MP, Hayes SC, Masuda A. Increasing willingness to experience obsessions: acceptance and commitment therapy as a treatment for obsessive-compulsive disorder. Behav Ther. 2006; 37(1): 3-13[DOI][PubMed]
  • 17. Izadi R, Asgari K, Neshatdust H, Abedi M. The Effect of acceptance and commitment therapy on the frequency and severity of symptoms of obsessive compulsive disorder. Zahedan J Res Med Sci. 2012; 14(10): 107-12
  • 18. Armstrong AB. Acceptance and commitment therapy for adolescent obsessive-compulsive disorder. [Dissertation]. 2011;
  • 19. Diagnostic and statistical manual of mental disorders. 2000;
  • 20. Navara CS, First NL, Schatten G. Phenotypic variations among paternal centrosomes expressed within the zygote as disparate microtubule lengths and sperm aster organization: correlations between centrosome activity and developmental success. Proc Natl Acad Sci U S A. 1996; 93(11): 5384-8[PubMed]
  • 21. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. Structured clinical interview for DSM-IV® axis II personality disorders (SCID-II), interview and questionnaire. 1997;
  • 22. Zanarini MC, Skodol AE, Bender D, Dolan R, Sanislow C, Schaefer E, et al. The Collaborative Longitudinal Personality Disorders Study: reliability of axis I and II diagnoses. J Pers Disord. 2000; 14(4): 291-9[PubMed]
  • 23. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989; 46(11): 1006-11[PubMed]
  • 24. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989; 46(11): 1012-6[PubMed]
  • 25. Mccurry SM, Hayes SC, Strosahl K, Wilson KG, Bissett RT, Pistorello J, et al. Measuring experiential avoidance: A preliminary test of a working model. Psychol Rec . 2004; 54: 553-78
  • 26. Woody SR, Steketee G, Chambless DL. Reliability and validity of the Yale-Brown obsessive-compulsive scale. Behav Res Ther. 1995; 33(5): 597-605
  • 27. Taylor S. Assessment of obsessions and compulsions: Reliability, validity, and sensitivity to treatment effects. Clin Psychol Rev. 1995; 15(4): 261-96
  • 28. Aboory S, Mehrya AH, Ghareeb A. [Comparing the effectiveness of cognitive-behavioral techniques, clomipramine and their combination in the treatment of obserssive compulsive disorder] . Iran J Psychiatry Clin Psychol. 1998; 4(1): 25-35
  • 29. Zargar F. Comparing the efficacy of acceptance-based behavior therapy to applied relaxation on female with generalized anxiety disorder [Dissertation]. 2011;
  • 30. Bakhtiary M. Mental disorders in patients with body disorder [Dissertation]. 2000;
  • 31. Sousa MB, Isolan LR, Oliveira RR, Manfro GG, Cordioli AV. A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder. J Clin Psychiatry. 2006; 67(7): 1133-9[PubMed]
  • 32. Cohen J. A power primer. Psychol Bull. 1992; 112(1): 155-9[PubMed]
  • 33. Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005; 162(1): 151-61[DOI][PubMed]
  • 34. Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet. 2009; 374(9688): 491-9[PubMed]
  • 35. Shareh H, Gharraee B, Atef-Vahid MK, Eftekhar M. Metacognitive therapy (MCT), fluvoxamine, and combined treatment in improving obsessive-compulsive, depressive and anxiety symptoms in patients with obsessive-compulsive disorder (OCD). Iran J Psychiatry Behav Sci. 2010; 4(2): 17-25
  • 36. Giasuddin NA, Nahar JS, Morshed NM, Balhara YP, Sobhan MA. Efficacy of combination of fluoxetine and cognitive behavioral therapy and fluoxetine alone for the treatment of obsessive compulsive disorder. Pak J Pharm Sci. 2013; 26(1): 95-8[PubMed]
  • 37. Foa EB, Franklin ME, Moser J. Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry. 2002; 52(10): 987-97[PubMed]
  • 38. Albert U, Brunatto C. Obsessive-compulsive disorder in adults: Efficacy of combined and sequential treatments. Clin Neuropsychiatry. 2009; 6: 83-93
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments